Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
Ariëns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, Kamsteeg M, Voorberg AN, Oosting AJ, de Ridder I, Sloeserwij A, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Ariëns LFM, et al. Among authors: oosting aj. J Am Acad Dermatol. 2021 Apr;84(4):1000-1009. doi: 10.1016/j.jaad.2020.08.127. Epub 2020 Sep 16. J Am Acad Dermatol. 2021. PMID: 32946967
Clinical evaluation of the effect of anti-allergic mattress covers in patients with moderate to severe asthma and house dust mite allergy: a randomised double blind placebo controlled study.
Rijssenbeek-Nouwens LH, Oosting AJ, de Bruin-Weller MS, Bregman I, de Monchy JG, Postma DS. Rijssenbeek-Nouwens LH, et al. Among authors: oosting aj. Thorax. 2002 Sep;57(9):784-90. doi: 10.1136/thorax.57.9.784. Thorax. 2002. PMID: 12200523 Free PMC article. Clinical Trial.
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.
Spekhorst LS, Ariëns LFM, van der Schaft J, Bakker DS, Kamsteeg M, Oosting AJ, de Ridder I, Sloeserwij A, Romeijn GLE, de Graaf M, Haeck I, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS. Spekhorst LS, et al. Among authors: oosting aj. Allergy. 2020 Sep;75(9):2376-2379. doi: 10.1111/all.14324. Epub 2020 May 5. Allergy. 2020. PMID: 32302412 Free PMC article. No abstract available.
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
Spekhorst LS, de Graaf M, Zuithoff NPA, van den Reek JMPA, Kamsteeg M, Boesjes CM, Romeijn GLE, Loman L, Haeck I, Oosting AJ, de Boer-Brand A, Touwslager WRH, Flinterman A, van Lynden-van Nes AMT, Gostynski AH, de Bruin-Weller MS, Schuttelaar ML. Spekhorst LS, et al. Among authors: oosting aj. JAMA Dermatol. 2022 Sep 1;158(9):1048-1056. doi: 10.1001/jamadermatol.2022.3014. JAMA Dermatol. 2022. PMID: 35947364 Free PMC article.
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Spekhorst LS, Boesjes CM, Loman L, Zuithoff NPA, Bakker DS, Kamphuis E, Kamsteeg M, Haeck IM, Oosting AJ, van Lumig PPM, van Lynden-van Nes AMT, Tupker RA, Flinterman A, Garritsen FM, Touwslager WRH, de Bruin-Weller MS, Schuttelaar MA, de Graaf M. Spekhorst LS, et al. Among authors: oosting aj. Br J Dermatol. 2023 Aug 24;189(3):327-335. doi: 10.1093/bjd/ljad159. Br J Dermatol. 2023. PMID: 37177895
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn MLE, Spekhorst LS, Haeck I, van der Gang LF, Dekkers CC, van der Rijst LP, Oosting AJ, van Lumig P, van Lynden-van Nes AMT, Tupker RA, Nijssen A, Flinterman A, Politiek K, Touwslager WRH, Christoffers WA, Stewart SM, Kamsteeg M, de Graaf M, de Bruin-Weller MS, Schuttelaar MA. Zhang J, et al. Among authors: oosting aj. J Am Acad Dermatol. 2024 Aug;91(2):300-311. doi: 10.1016/j.jaad.2024.04.026. Epub 2024 Apr 21. J Am Acad Dermatol. 2024. PMID: 38653344 Free article.
Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.
Boesjes CM, Kamphuis E, de Graaf M, Spekhorst LS, Haeck I, van der Gang LF, Loman L, Zuithoff NPA, Dekkers C, van der Rijst LP, Romeijn GLE, Oosting AJ, Gostynksi A, van Lynden-van Nes AMT, Tupker RA, van Tuyll van Serooskerken AM, Flinterman A, Politiek K, Touwslager WRH, Christoffers WA, Stewart SM, Kamsteeg M, Schuttelaar MA, de Bruin-Weller MS. Boesjes CM, et al. Among authors: oosting aj. JAMA Dermatol. 2024 Oct 1;160(10):1044-1055. doi: 10.1001/jamadermatol.2024.2517. JAMA Dermatol. 2024. PMID: 39110432
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels.
Dekkers C, Zuithoff N, Bakker D, Knol E, Wevers A, Touwslager W, Christoffers W, Prosje P, van Lynden-van Nes A, van Lümig P, Kamsteeg M, Oosting AJ, Schuttelaar MLA, Haeck I, de Graaf M, van Wijk F, de Bruin-Weller M. Dekkers C, et al. Among authors: oosting aj. Allergy. 2024 Dec 14. doi: 10.1111/all.16414. Online ahead of print. Allergy. 2024. PMID: 39673366
The effect of anti-allergic mattress encasings on house dust mite-induced early- and late-airway reactions in asthmatic patients. A double-blind, placebo-controlled study.
Rijssenbeek-Nouwens LH, Oosting AJ, De Monchy JG, Bregman I, Postma DS, De Bruin-Weller MS. Rijssenbeek-Nouwens LH, et al. Among authors: oosting aj. Clin Exp Allergy. 2002 Jan;32(1):117-25. doi: 10.1046/j.0022-0477.2001.01256.x. Clin Exp Allergy. 2002. PMID: 12002728 Clinical Trial.
20 results